Latest Share Chat

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

Fri, 19th Feb 2021 12:40

Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Non-Executive Director Martin Diggle sells 1.3 million shares via Vulpes Life Sciences Fund at average 25.50 pence, worth about GBP318,750, on Wednesday. Vulpes had sold 400,000 shares on Tuesday. Vulpes now has 116.6 million shares, a 14.3% stake.

Current stock price: 25.40p, down 7.6% Friday

Year-to-date change: up 81%

By Tom Waite; thomaslwaite@alliancenews.com

Related Shares

More News

26 Mar 2024 14:00

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic....

5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...

30 Jan 2024 13:56

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.

17 Jan 2024 14:26

IN BRIEF: Scancell approved by MHRA to add new cohort to Scope trial

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval fro...

19 Dec 2023 13:35

Scancell raises GBP12 million in total from fundraise

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of share...